Incysus Therapeutics Scientific Co-Founder Lawrence Lamb, PhD to Present at 8th International Gamma-Delta T Cell Conference
Incysus Therapeutics, Inc.
Jun. 08, 2018
Symposium Title: “Targeting of chemotherapy-induced NKG2DL by localized repetitive γδ T cell infusions: a rational therapeutic design for elimination of minimal residual primary high grade gliomas”
NEW YORK, June 08, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, announced today that Lawrence S. Lamb, PhD, Professor of Medicine and Director of the Cell Therapy Laboratory at the University of Alabama at Birmingham (UAB) and Scientific Co-Founder of Incysus, will present at a scientific symposium on June 10, 2018 during the 8th International Gamma-Delta T Cell Conference, in Bordeaux, France.
The symposium, titled, “γδ T Cells in Immunotherapy” will include two sessions. The first session will be co-chaired by Dieter Kabelitz, MD, Professor and Director of the Institute of Immunology at the University of Kiel. Dr. Kabelitz is a founding member of the Incysus Scientific Advisory Board.
Scientific Session 9.1 Title: γδ T Cells in Immunotherapy I Date and Time: Sunday, June 10, 2018, 9:00 a.m. UTC Co-chair: Dieter Kabelitz Scientific Session 9.2 Title: γδ T Cells in Immunotherapy II Date and Time: Sunday, June 10, 2018, 11:45 a.m. UTC Speaker: Lawrence S. Lamb, Ph.D. Targeting of chemotherapy-induced NKG2DL by localized repetitive γδ T cell infusions: a Presentation: rational therapeutic design for elimination of minimal residual primary high grade gliomas
About The 8th International Gamma-Delta T Cell ConferenceThe 8th International Gamma-Delta T Cell Conference will be held in Bordeaux, France from June 7-10, 2018. With the new companies targeting γδ T cells for cancer immunotherapy, including Incysus, it is an exciting time to come together. The goals of the conference are to bring together investigators from around the world working on γδ T cells to share and discuss unpublished results, refine existing and develop new paradigms, and identify directions for future research.
About Incysus Therapeutics, Inc. Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, our technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. For more information, visit www.incysus.com.
Contact:Incysus Therapeutics, Inc.(646) email@example.com